Wave Life Sciences WVE GB — Deferred Tax Assets Operating Loss Carryforwards

Similar metrics at other companies

VSATGB — Deferred Tax Assets Operating Loss Carryforwards

$64.2M—

LACCA — Deferred Tax Assets Operating Loss Carryforwards

$16.2M+1.9%

LACUS — Deferred Tax Assets Operating Loss Carryforwards

$288.5M+12.0%

LSAKUS — Deferred Tax Assets Operating Loss Carryforwards

$30.8M—

LSAKZA — Deferred Tax Assets Operating Loss Carryforwards

$212.1M—

VHI

VHIUS — Deferred Tax Assets Operating Loss Carryforwards

$12.2M—

FAQ

What is Wave Life Sciences's GB — deferred tax assets operating loss carryforwards?

Wave Life Sciences (WVE) reported GB — deferred tax assets operating loss carryforwards of $414.7M in Q4 2025.

How has Wave Life Sciences's GB — deferred tax assets operating loss carryforwards changed year-over-year?

Wave Life Sciences's GB — deferred tax assets operating loss carryforwards increased by 22.2% year-over-year, from $339.5M to $414.7M.

What does GB — deferred tax assets operating loss carryforwards mean?

This metric represents the value of tax benefits derived from historical operating losses that can be carried forward to offset future taxable income. It is a significant asset for companies in growth or R&D-heavy phases, indicating potential future tax savings. Investors track this to estimate the company's ability to shield future profits from taxation.